• No results found

18 results with keyword: 'gemtuzumab ozogamicin mylotarg treatment myeloid leukemia ongoing trials'

Gemtuzumab Ozogamicin (Mylotarg) for the Treatment of Acute Myeloid Leukemia – Ongoing Trials

26 Amadori S, Suciu S, Stasi R, Willemze R, Mandelli F, Selleslag D, Denzlinger C, Muus P, Stauder R, Berneman Z, Pruijt J, Nobile F, Cassibba V, Marie JP, Beeldens F, Baila

Protected

N/A

6
0
0
2021
The role of gemtuzumab ozogamicin in acute leukaemia therapy

& Mylotarg Study Group (2003) Gemtuzumab ozogamicin in combination with induction chemo- therapy for the treatment of patients with de novo acute myeloid leukemia: two

Protected

N/A

12
0
0
2021
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin

Gemtuzumab ozogamicin (Mylotarg) as single-agent treatment for frail patients 61 years of age and older with acute myeloid leukemia: fi nal results of AML-15B, a phase 2 study of

Protected

N/A

10
0
0
2020
Rapid Efficacy of Gemtuzumab Ozogamicin in Refractory AML Patients with Organ Dysfunctions

Keywords: acute myeloid leukemia; patients with organ dysfunction; gemtuzumab ozogamicin.. 26

Protected

N/A

8
0
0
2020
Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia

Gemtuzumab Ozogamicin (Mylotarg [Registered]) Expanded Access Protocol for Treatment of Patients in the United States with Relapsed/ Refractory Acute Myelogenous Leukemia Who

Protected

N/A

11
0
0
2021
Gemtuzumab ozogamicin in the treatment of adult acute myeloid leukemia

(2009) Prelimi- nary results of Southwest Oncology Group Study S0106: An international intergroup phase 3 randomized trial com- paring the addition of gemtuzumab ozogamicin to stan-

Protected

N/A

9
0
0
2020
The Development of Personalized Medicine: Acute Myeloid Leukemia as a Model

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the

Protected

N/A

12
0
0
2020
Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of the ALFA-0701 trial

Clinical impact of gene mutations and lesions detected by SNP-array karyotyping in acute myeloid leukemia patients in the context of gemtuzumab ozogamicin treatment: Results of

Protected

N/A

17
0
0
2020
Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia

Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by

Protected

N/A

13
0
0
2020
Reinduction Chemotherapy with  Gemtuzumab Ozogamicin and  Intermediate/High Dose Cytarabine:  A Single Center Experience

We performed a retrospective analysis of 9 patients with acute myeloid leukemia (AML) treated with gemtuzumab ozogamicin (GO) plus cytarabine as a salvage regimen (GO reinduction)

Protected

N/A

8
0
0
2020
The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody–drug conjugate for the treatment of newly diagnosed acute myeloid leukemia

A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Burnett AK, Russell NH, Hills RK,

Protected

N/A

8
0
0
2020
Gemtuzumab ozogamicin in children with relapsed or refractory acute myeloid leukemia: a report by Berlin-Frankfurt-Münster study group

Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Efficacy of

Protected

N/A

10
0
0
2021
Mylotarg has potent anti leukaemic effect : a systematic review and meta analysis of anti CD33 antibody treatment in acute myeloid leukaemia

Li X, Xu SN, Qin DB, Tan Y, Gong Q, Chen JP (2014) Effect of adding gemtuzumab ozogamicin to induction chemotherapy for new- ly diagnosed acute myeloid leukemia: a meta-analysis

Protected

N/A

14
0
0
2020
PIX/ASA 7.x and above: Mail (SMTP) Server Access on the DMZ Configuration Example

Refer to PIX/ASA 7.x and above: Mail Server Access on Inside Network Configuration Example for instructions on how to set up the PIX/ASA Security Appliance for access to a

Protected

N/A

6
0
0
2021
The prevalent predicament of relapsed acute myeloid leukemia

Gemtuzumab ozogamicin-based salvage, followed by allogeneic hematopoi- etic stem cell transplantation, is highly effective in young patients with core binding factor (CBF) acute

Protected

N/A

6
0
0
2021
MRD assessed by WT1 and N PM1 transcript levels identifies distinct outcomes in AML patients and is influenced by gemtuzumab ozogamicin

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Renneville A, Abdelali

Protected

N/A

9
0
0
2020
A Study on the Bezier Variant of Certain Bernstein Durrmeyer Operator

Gupta3 introduced a different Durrmeyer type modification of the Bernstein polynomials and estimated the rate of convergence for functions of bounded variation.. The

Protected

N/A

8
0
0
2022
Εφημ. "Ελευθεροτυπία, Ένθετο "Ιστορικά" Τ. 207

or Bperovoi ßpioxovrov oxöpn oug OepponüÄeg xor n Oeon roug ntov röroirepo euroEoÄng. Or re- Äeurcrior niezqv oEöpnro ornv A8nvo yro noporo- on rou nol,ö1rou Uexprs

Protected

N/A

49
0
0
2021

Upload more documents and download any material studies right away!